Corpus Christi Dialysis is a medicare approved dialysis facility center in Corpus Christi, Texas and it has 26 dialysis stations. It is located in Nueces county at 2733 Swantner Dr, Corpus Christi, TX, 78404. You can reach out to the office of Corpus Christi Dialysis at (361) 855-4911. This dialysis clinic is managed and/or owned by Davita. Corpus Christi Dialysis has the following ownership type - Profit. It was first certified by medicare in August, 1987. The medicare id for this facility is 452514 and it accepts patients under medicare ESRD program.
| Name | Corpus Christi Dialysis |
|---|---|
| Location | 2733 Swantner Dr, Corpus Christi, Texas |
| No. of Dialysis Stations | 26 |
| Medicare ID | 452514 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2733 Swantner Dr, Corpus Christi, Texas, 78404 | |
| (361) 855-4911 | |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
| NPI Number | 1477509487 |
| Organization Name | Corpus Christi Dialysis |
| Doing Business As | Isd Renal Inc |
| Address | 2733 Swantner St Corpus Christi, Texas, 78404 |
| Phone Number | (361) 855-4911 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 64% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 20% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 14% |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 19% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 55% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 12% |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 63 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 25 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 122 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1166 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Corpus Christi Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 129 |
| Hypercalcemia patient months | 1254 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 134 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 12 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 103 |
| Patient months included in arterial venous fistula and catheter summaries | 742 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 54 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 105 |
| Hospitalization Rate in facility | 156.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 262.8 |
| Hospitalization Rate: Lower Confidence Limit | 100.6 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Corpus Christi Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 28.2 |
| Readmission Rate: Lower Confidence Limit | 14.5 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Corpus Christi Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .62 (As Expected) |
| SIR: Upper Confidence Limit | 1.38 |
| SIR: Lower Confidence Limit | .23 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Corpus Christi Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 95 |
| Transfusion Rate in facility | 43.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 86.1 |
| Transfusion Rate: Lower Confidence Limit | 24 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Corpus Christi Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 639 |
| Mortality Rate in facility | 20.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.6 |
| Mortality Rate: Lower Confidence Limit | 16.3 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago
Corpus Christi Dialysis Location: 2733 Swantner Dr, Corpus Christi, Texas, 78404 Phone: (361) 855-4911 |
BAY Area Dialysis Corpus Christi Location: 1647 South Alameda, Corpus Christi, Texas, 78404 Phone: (361) 888-7547 |
Fresenius Medical Care Calallen Location: 4147 G Five Points Rd, Corpus Christi, Texas, 78410 Phone: (361) 242-3300 |
Davita Coastal Dialysis Location: 4300 2-2 S Padre Island Dr, Corpus Christi, Texas, 78411 Phone: (361) 855-9449 |
BAY Area Dialysis Southside Location: 4112 S Staples Ste Ab, Corpus Christi, Texas, 78411 Phone: (361) 814-0168 |
News Archive
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Studies of health effects of alcohol consumption may underestimate the risks of imbibing, particularly for younger people, according to a new study in the Journal of Studies on Alcohol and Drugs.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
Medco Health Solutions, the largest U.S. pharmacy benefit manager, on Monday agreed to pay $155 million to settle fraud allegations brought by the federal government and several former company employees, the Newark Star-Ledger reports (Silverman, Newark Star-Ledger, 10/24).
› Verified 4 days ago